Julio Delgado, Senior Consultant in Haematology at Hospital Clínic de Barcelona, shared on LinkedIn:
“With some difficulty due to Microsoft’s problems, I am delighted to share that we have already had the first clinical trial kick-off visit with ARI-HER2.
The first CART product of Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) directed against a solid tumor, in this case HER2+ breast cancer.
The clinical trial is practically approved in the absence of minimal details.
Many thanks to all the participants, but especially to Víctor Albarrán Fernández, Aleix Prat, Tomás Pascual Martínez, the rest of the ICAMS colleagues, Miquel Lozano, Paola Charry, Azucena González, Manel Juan Otero, Eulalia Olesti, Sara Varea Latorre, Laura Angelats, Alba Rodríguez-Garcia, Sonia Guedan and his team, the colleagues of SOLTI cancer research and, above all, Asociación Española Contra el Cáncer, who have agreed to finance it.
Kick-off visits will take place soon in Hospital 12 de Octubre and Clínica Universidad de Navarra.
We hope to be able to include the first patients in January 2027.”
Tomás Pascual Martínez, Head Breast and Gynecologic Cancer Section, Medical Oncology Deparment at Hospital Clínic de Barcelona, added:
“A very important step for breast cancer research!
I am very excited to be part of this project that will allow the CAR-T therapy developed in the Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) to be used in the treatment of patients with HER2+ breast cancer.
A great example of how collaboration between basic, translational and clinical research can transform innovation into new therapeutic opportunities for our patients.
Congratulations to Julio Delgado Aleix Prat , Víctor Albarrán Fernández and all the teams involved SOLTI cancer research for the enormous work done, and a special thanks to the Asociación Española Contra el Cáncer for making it possible.”
You may also be interested in:
Aleix Prat: A Major Step Toward Bringing CAR-T Therapies to Solid Tumors
